SEC Form 4 · accession 0001363213-16-000071
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Friedhelm Blobel
Officer — President & CEO · Director
Period of report
Mar 28, 2016
Accepted (ET)
Mar 30, 2016 · 11:20 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 28, 2016 | M | 840 | $2.49 | A | 206,092 | D | |
| Common Stock | Mar 28, 2016 | S | 840 | $9.2878 | D | 205,252 | D | |
| Common Stock | Mar 28, 2016 | M | 9,160 | $2.49 | A | 214,412 | D | |
| Common Stock | Mar 28, 2016 | S | 9,160 | $9.2878 | D | 205,252 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2,F3 | $2.49 | Mar 28, 2016 | M | 840 | D | — | Jun 2, 2016 | Common Stock | 840 | 508,320 | D |
| Non-Qualified Stock Option (right to buy)F2,F3 | $2.49 | Mar 28, 2016 | M | 9,160 | D | — | Jun 2, 2016 | Common Stock | 9,160 | 499,160 | D |
Explanation of responses
- F1The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2014.
- F2Granted under the Issuer's 2005 Equity Incentive Plan.
- F3Provided the reporting person remains employed by or acting as a consultant to the Company, the option will become exercisable in four equal annual installments on 6/02/07, 6/02/08, 6/02/09 and 6/02/10.